The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis

Carcinogenesis

Volumn 19, Issue 1, 1998, Pages 87-91

  Mahmoud, N N ^a   Boolbol, S K ^a,b   Dannenberg, A J ^a,b   Mestre, J R ^b   Bilinski, R T ^a   Martucci, C ^b   Newmark, H L ^b   Chadburn, A ^a   Bertagnolli, M M ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b STRANG CANCER PREVENTION CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SULINDAC SULFIDE;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HOMOZYGOTE; INTESTINE CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; APOPTOSIS; FEMALE; GENES, APC; HETEROZYGOTE; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PRODRUGS; SULINDAC;

EID: 0031823483     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/19.1.87     Document Type: Article

References (36)

1. Thun, M.J., Namboodiri, B.S. and Heath, C.W. (1991) Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325, 1593-1596.
2. Giovannucci, E., Egan, K.M., Hunter, D.J., Stampfer, M.J., Colditz, G.A., Willen, W.C. and Speizer, F.E. (1995) Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333, 609-614.
3. Min mouse model by the non-steroidal anti-inflammatory drug piroxicam. Cancer Res., 56, 710-714.
4. Reddy, B.S., Maruyama, H. and Kelloff, G. (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a non-steroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47, 5340-5346.
5. Moorghen, M., Ince, P., Finney, K.J., Sunter, J.P., Appleton, D.R. and Watson, A.J. (1988) A protective effect of sulindac against chemically-induced primary colonie tumors in mice. J. Pathol., 156, 341-347.
6. Rao, C.V., Rivenson, A., Simi, B., Zang, E., Kellogg, G., Steele, V. and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res., 55, 1464-1472
7. Reddy, B.S., Rao, C.V., Rivenson, A. and Kelloff, G.J. (1993) Inhibitory effect of aspirin on azoyxmethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (Lond.), 14, 1493-1497.
8. Reddy, B.S., Tokumo, K., Kulkarni, N., Aligia, C. and Kelloff, G. (1992) Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis, 13, 1019-1023.
9. Metzger, U., Meier, J., Uhlschmid, G. and Weihe, H. (1984) Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis. Colon Rectum, 27, 366-369.
10. Narisawa, T., Staoh, M., Sano, M. and Takahashi, T. (1993) Inhibition of initiation and promotion on N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroidal anti-inflammatory agent indomethacin. Carcinogenesis (Lond.), 14, 1493-1497.
11. Pollard, M. and Luckert, P.H. (1984) Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett., 25, 117-121.
12. Klein, W.A., Miller, H.H., Anderson, M. and DeCosse, J.J. (1987) The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer, 60, 2863-2868.
13. Sano, H., Kawahito, Y., Wilder, R.L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M. and Hla, T. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55, 3785-3789.
14. Kargman, S.L., O'Neill, G.P., Vickers, P.J., Evans, J.F., Mancini, J.A. and Jothy, S. (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55, 2556-2559.
15. Boolbol, S.K., Dannenberg, A.J., Chadburn, A., et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56, 2556-2560.
16. Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylind, L.M., Celano, P., Booker, S.V., Robinson, C.R. and Offerhaus, G.J. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313-1316.
17. Waddell, W.R. and Loughry, R.W. (1983) Sulindac for polyposis of the colon. J. Surg. Oncol., 24, 83-87.
18. Waddell, W.R., Ganser, G.F., Cerise, E.J. and Loughry, R.W. (1989) Sulindac for polyposis of the colon. Am. J. Surg., 157, 175-179.
19. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M. and Attali, P. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101, 635-639.
20. Nugent, K.P., Spigelman, A.D. and Phillips, R.K.S. (1996) Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis. Colon Rectum, 39, 659-662.
21. Shen, T.Y. and Winter, C.A. (1977) Chemical and biological studies on indomethacin, sulindac, and their analogs. Adv. Drug Res., 12, 89-245.
22. Duggan, D.E., Hooke, K.F., Risley, E.A., Chen, T.-Y. and Van Arman, G. (1977) Identification of the biologically active form of sulindac. J. Pharm. Exp. Therapeut., 201, 8-13.
23. Thompson, H.J., Briggs, S., Paranka, N.S., Piazza, G.A., Brendel, K., Gross, P.H., Sperl, G.J., Pamukcu, R. and Ahnen, D.J. (1995) Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl Cancer Inst., 16, 1259-1260.
24. Thompson, H.J., Jiang, C., Lu, J., Mehta, R.G., Piazza, G.A., Paranka, N.S., Pamukcu, R. and Ahnen, D.J. (1997) Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 57, 267-271.
25. Hixson, L.J., Alberts, D.S., Krutzsch, M., et al. (1994) Antiproliferative effect of non-steroidal anti-inflammatory drugs (NSAIDs) against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev., 3, 433-438.
26. Piazza, G.A., Kulchak Rahm, A.L., Krutzsch, M., et al. (1995) Antineoplastic drugs sulindac sulride and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55, 3110-3116.
27. Su, L.-K., Kinzler, K.W., Vogelstein, B., Preisinger, A.C., Moser, A.R., Luongo, C., Gould, K.A. and Dove, W.F. (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science, 256, 668-670.
28. Moser, A.R., Pitot, H.C. and Dove, W.F. (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322-324.
29. Luongo, C., Moser, A.R., Gledhill, S. and Dove, W.F. (1994) Loss of APC+ in intestinal adenomas from Min mice. Cancer Res., 54, 5947-5952.
30. Bedi, A., Pasricha, P.J., Akhtar, A.J., Barber, J.P., Bedi, G.C., Giardiello, F.M., Zehnbauer, B.A., Hamilton, S.R. and Jones, R.J. (1995) Inhibition of apoptosis during development of colorectal cancer. Cancer Res., 55, 1811-1816.
31. Tsujii, M. and DuBois, R.N. (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83, 493-501.
32. Pasricha, P.J., Bedi, A., O'Connor, K., Rashid, A., Akhtar, A.J., Zahurak, M.L., Piantadosi, S., Hamilton, S.R. and Giardiello, F.M. (1995) The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterohgy, 109, 994-998.
33. Rigas, B., Goldman, I.S. and Levine, L. (1993) Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122, 518-523.
34. 716 knockout mice by inhibition of cyclooxygenase 2. Cell, 87, 803-809.
35. Reddy, B.S., Rao, C.V. and Siebert, K. (1996) Evaluation of cyclo-oxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56, 4566-4569.
36. Piazza, G.A., Alberts, D.S., Hixson, L.J., et al. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57, 2909-2915.